BSX vs ENOV Stock Comparison

Compare BSX and ENOV across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.

Market data as of Sep 11, 2026 market close· AIQ score gap 2 points
BSX
Healthcare
vs
ENOV
Healthcare
BSX
Boston Scientific Corporation
Leads
Price
$42.98
Day move
-0.28%
AIQ Score
49/100
Best edge
Quality
Sector
Healthcare
ENOV
Enovis Corporation
Price
$19.28
Day move
+4.73%
AIQ Score
47/100
Best edge
Value
Sector
Healthcare

What is the main difference between BSX and ENOV?

BSX leads the current stock comparison as Boston Scientific Corporation, with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Boston Scientific Corporation vs Enovis Corporation

Data as of Sep 11, 2026· market close· Healthcare· Coverage 66/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 2/10

BSX leads

BSX leads by 2 AIQ points, primarily on Quality, but the lead has narrowed from 9 points over 30 sessions. Wall Street currently favors ENOV on target upside.

Fragile: 2 of 6 evidence groups support BSX, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 2 of 6Comparison trend: Weakening
BSX

Boston Scientific Corporation

Leads
AIQ Score
49/100
AIQ Edge Score
6/10
ENOV

Enovis Corporation

AIQ Score
47/100
AIQ Edge Score
5/10

The Algovestiq AIQ Score currently favors BSX over ENOV, 49 versus 47 as of Sep 11, 2026. BSX's advantage is driven primarily by stronger quality, while ENOV holds the stronger value profile. BSX also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors ENOV. 2 of 6 covered evidence groups favor BSX today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. BSX lead: Weakening — the AIQ differential moved from 9 to 2 points over 30 sessions.

Compare Boston Scientific Corporation and Enovis Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price-return comparison using available daily close history.

BSX
-2.8%
ENOV
-73.9%

Total return comparison

Growth of $10,000

BSX $9,718 · ENOV $2,613

Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.

Compare BSX and ENOV against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BSX advantage
0
ENOV advantage
  • Quality67 vs 42
    BSX +25
  • Value58 vs 74
    ENOV +16
  • Momentum23 vs 24
    Even
  • Risk Resilience41 vs 40
    Even

2 of 6 evidence groups favor BSX. BSX’s edge is concentrated in quality; ENOV keeps a meaningful value edge.

What changed since the last close

Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.

BSX-1 AIQ

Largest factor move: Risk Resilience -2

New signals

  • BB Lower Band Breach bullish, volatility, short horizon
  • 52-Week Low Proximity bearish, risk, long horizon (1.4%)
ENOV0 AIQ

No factor moved materially.

No new signals fired.

BSX's lead narrowed by 1 AIQ points in the latest snapshot.

Deeper signal detail for each name lives on its own signals page — BSX and ENOV both carry a full feed there.

The central trade-off

BSX (Boston Scientific Corporation): the stronger current systematic profile, led by quality.

ENOV (Enovis Corporation): the counter-case, on value, valuation, analyst expectations — but at materially higher volatility, 77.6% against 42.3%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BSX

BSX on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

ENOV

ENOV on combined revenue and EPS growth.

Value

ENOV

ENOV on the peer-relative Value factor, by 16 points.

Momentum

Even

The two are level on Momentum.

Lower downside

BSX

BSX carries the lower 1-month annualized volatility.

Analyst upside

ENOV

ENOV on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors BSX, analyst targets favor ENOV. That disagreement is the most useful thing on this page.

MeasureBSXENOVNote
Implied upside to target+70.1%+85.4%ENOV has more room
Target dispersion+68.4%+67.1%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering205Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 6 covered evidence groups favor BSX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreEven49 vs 47
FundamentalsBSXon balancerevenue growth 4.6% vs -1.1%; EPS growth -31.1% vs 86.7%; TTM ROE 14.9% vs -68.2%; gross margin 71.2% vs 57.4%; operating margin 21.5% vs 4.1% — BSX takes 4 of 5 decided legs, not all of them
ValuationENOVValue 58 vs 74
TechnicalsBSXPrice vs 50-day -8.4% vs -23.9%; vs 200-day -34.7% vs -24.8%
Risk ResilienceEvenRisk Resilience 41 vs 40
Analyst expectationsENOVTarget upside 70.1% vs 85.4%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BSX and ENOV and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
  • Only 2 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BSX.

How the comparison changed

119 daily snapshots · May 4 Sep 10

BSX lead: Weakening — the AIQ differential moved from 9 to 2 points over 30 sessions.

May 4BSX leads above the line · ENOV leads belowSep 10
Today
BSX +2
49 vs 47
7 sessions ago
BSX +8
55 vs 47
30 sessions ago
BSX +9
63 vs 54
90 sessions ago
ENOV +4
54 vs 58

The lead changed hands 5 times in this window, most recently on Jul 31 when BSX moved ahead of ENOV.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BSXConflicted

2 bullish / 5 bearish / 1 neutral, conflicted

  • Death Cross Active bearish, trend, long horizon (40.53%)
  • BB Lower Band Breach bullish, volatility, short horizon
  • Keltner Channel Breakdown bearish, volatility, short horizon
ENOVConflicted

2 bullish / 3 bearish / 1 neutral, conflicted

  • Golden Cross Active bullish, trend, long horizon (2.93%)
  • Keltner Channel Breakdown bearish, volatility, short horizon
  • RSI Oversold - Potential Bounce bullish, momentum, short horizon

BSX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BSXConfirmed weakness

Price and the AIQ Score both moved down over the latest session (price -0.28%, AIQ -1 points).

ENOVNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +4.73%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ENOV closes the Quality gap — currently 25 points behind, the largest single contributor to BSX's edge.
  2. 2ENOV's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it.
  3. 3BSX's conflicting signal state resolves bearish — it currently carries 2 bullish and 5 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 2-point move would eliminate BSX's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

BSX leads on balance
MetricBSXENOV
Revenue growth (YoY)4.6%-1.1%
EPS growth (YoY)-31.1%86.7%
Gross margin71.2%57.4%
Operating margin21.5%4.1%
Return on equity (TTM)14.9%-68.2%
Debt to equity0.510.93

Performance

ENOV leads 4 of 6 windows
MetricBSXENOV
1 week (5 sessions)-10.9%-8.9%
1 month (20 sessions)-16.2%-25.4%
3 months (63 sessions)-10.8%-16.2%
6 months (126 sessions)-38.1%-25.9%
Year to date-54.8%-27%
1 year (252 sessions)-59.8%-41%

Technicals

BSX has the stronger structure
MetricBSXENOV
RSI (14)29.816.7
ADX (14)1724.5
Price vs 50-day-8.4%-23.9%
Price vs 200-day-34.7%-24.8%
Volatility (1M, annualized)42.3%77.6%

Risk

Split
MetricBSXENOV
Beta0.181.49
Sharpe ratio-2.33-0.58
Sortino ratio-2.56-0.86
Max drawdown-60.6%-44.8%
Current drawdown-60.1%-44.8%
Annualized volatility38%63.2%
Value at risk (95%)-3.6%-6.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BSX or ENOV?

On the Algovestiq AIQ Score, BSX is the stronger of the two as of Sep 11, 2026, scoring 49 against ENOV's 47. The edge comes from quality. ENOV is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BSX or ENOV the better buy right now?

BSX carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 2 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.

Why does the AIQ Score favor BSX over ENOV?

The composite weights Quality, Value, Momentum and Risk Resilience. BSX leads Quality by 25 points; ENOV leads Value by 16 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BSX or ENOV?

Analyst price targets imply +70.1% upside for BSX and +85.4% for ENOV, so the Street currently favors ENOV. That points the opposite way to the AIQ Score, which favors BSX. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BSX or ENOV?

ENOV is the better-valued of the two on the peer-relative Value factor. ENOV on the peer-relative Value factor, by 16 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BSX or ENOV?

ENOV on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BSX or ENOV?

The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BSX or ENOV?

BSX is the more resilient of the two, so the other name carries the higher downside risk. BSX carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BSX more profitable than ENOV?

BSX leads on the comparable margin measures — gross margin 71.2% vs 57.4%; operating margin 21.5% vs 4.1%; ttm roe 14.9% vs -68.2%.

Is BSX's lead over ENOV getting stronger or weaker?

BSX lead: Weakening — the AIQ differential moved from 9 to 2 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 5 times in that window, most recently on 2026-07-31, when BSX moved ahead of ENOV.

What would change the BSX vs ENOV verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ENOV closes the Quality gap — currently 25 points behind, the largest single contributor to BSX's edge; ENOV's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it; BSX's conflicting signal state resolves bearish — it currently carries 2 bullish and 5 bearish rules at once; the narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 2-point move would eliminate BSX's advantage entirely.

What do the current signals say about BSX and ENOV?

BSX: 2 bullish / 5 bearish / 1 neutral, conflicted. ENOV: 2 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BSX is Death Cross Active (bearish, long horizon). On ENOV it is Golden Cross Active (bullish, long horizon).

Compare BSX and ENOV with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.